The global autoimmune disease diagnosis market size reached US$ 3.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2027, exhibiting a growth rate (CAGR) of 6.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

An autoimmune disease refers to a condition wherein the immune system attacks and destroys healthy cells, tissues, and organs of the body. In the longer run, it can also lead to abnormal growth of an organ and changes in organ function. Currently, more than 80 different autoimmune disorders have been identified by scientists, out of which Systemic Lupus Erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes, are the most common. Depending on the disorder, the doctor uses a combination of methods, which include a physical examination, medical history, blood tests, biopsy, and X-rays, to provide an effective diagnosis. They prescribe anti-inflammatory and immunosuppressant drugs, physical therapy, surgery, and injections, to control the overactive immune response and provide relief from symptoms.

Owing to the rising prevalence of autoimmune diseases, healthcare professionals around the world are focusing on the adoption of advanced technologies to conduct multiple tests with faster and more precise results. Apart from this, a large number of research and diagnostics institutes are undertaking public awareness campaigns to educate individuals about autoimmune diseases and their possible treatments and diagnosis, which is positively influencing the market growth. Furthermore, several governing authorities, along with non-governing organizations, are funding various programs to develop novel therapeutics. For instance, the AMP RA/SLE Program, launched by the Accelerating Medicines Partnership (AMP), is a public-private partnership between the National Institutes of Health (NIH), the US Food and Drug Administration (FDA) and multiple non-profit organizations. The program aims to identify relevant drug targets for the treatment of autoimmune diseases.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global autoimmune disease diagnosis market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, disease type, test type and end-user.

Breakup by Product Type:

Consumables and Assay Kits
Instruments

Breakup by Disease Type:

Systemic Autoimmune Disease
Rheumatoid Arthritis
Psoriasis
Systemic Lupus Erythematosus (SLE)
Multiple Sclerosis
Others
Localized Autoimmune Disease
Inflammatory Bowel Disease
Type 1 Diabetes
Thyroid
Others

Breakup by Test Type:

Routine Laboratory Tests
Inflammatory Markers
Autoantibodies and Immunologic Tests
Others

Breakup by End-User:

Clinical Laboratories
Hospitals
Others

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, AESKU.GROUP, Danaher Corp., bioM?rieux SA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hemagen Diagnostics, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., and Trinity Biotech plc.

Key Questions Answered in This Report
1. What is the size of the global autoimmune disease diagnosis market?
2. What has been the impact of COVID-19 on the global autoimmune disease diagnosis market?
3. What is the expected growth rate of the global autoimmune disease diagnosis market?
4. What are the key factors driving the global autoimmune disease diagnosis market?
5. What is the breakup of the global autoimmune disease diagnosis market based on the product type?
6. What is the breakup of the global autoimmune disease diagnosis market based on the disease type?
7. What is the breakup of the global autoimmune disease diagnosis market based on the test type?
8. What are the key regions in the global autoimmune disease diagnosis market?
9. Who are the key players/companies in the global autoimmune disease diagnosis market?